Comet Bio reports positive results for prebiotic Arrabina
Comet Bio said that Arrabina, its arabinoxylan plant fiber extract, has delivered positive clinical trial results with its gastrointestinal (GI) tolerability no different than placebo.
The results are from a completed randomized, placebo-controlled, crossover clinical trial that assessed the gastrointestinal tolerability and prebiotic effects of Arrabina.
Comet Bio said that results show that consumers can take up to 12 grams per day of Arrabina without any negative gut or bowel reaction. The clinical study also found that the arabinoxylan plant fiber extract promotes the growth of bifidobacteria, thereby confirming its prebiotic function.
The company claimed that Arrabina offers a solution to the prebiotic problem of causing gastrointestinal distress and bloating, which makes it difficult for people to incorporate them into their healthy diets.
The clinical trial, which was administered by a research organization called Biofortis, was completed with 44 healthy individuals who consumed the arabinoxylan plant fiber extract for three weeks at six grams or 12 grams per day or a placebo. The clinical study came to the conclusion that even at a high dosage of 12 grams per day, there were no statistical differences in gastrointestinal scores between Arrabina and the placebo.
Rich Troyer – Comet Bio CEO said: “Our proprietary water extraction technology makes it possible to produce Arabinoxylan and other nutrition from upcycled crop leftovers.
“Our process uses water and pressure to produce Arabinoxylan as a fully-soluble powder with superior functionality. Arrabina’s low viscosity means it will not gel or impact texture when added as a supplement to protein powders or as a fiber boost for nutrition bars, baked goods, and drinks.”